A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens
收藏DataCite Commons2026-01-28 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012700/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to assess the objective response rate (change in tumor size from baseline) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer treated with Nivolumab (BMS-936558) after failure of 2 prior systemic regimens
提供机构：
Vivli
创建时间：
2026-01-28
